CytomX Therapeutics (CTMX) Change in Accured Expenses (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Change in Accured Expenses data on file, last reported at -$3.6 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 70.89% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.5 million (up 37.78% YoY) and the FY2025 annual result came in at -$3.0 million, up 68.33% from the prior year.
• Change in Accured Expenses eased to -$3.6 million in Q1 2026, from $486000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $2.0 million in Q3 2024 to a low of -$7.4 million in Q1 2023.
• A 5-year average of -$1.9 million and a median of -$1.7 million in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 242.39% in 2023, down 932.12% in 2023.
• Tracing CTMX's Change in Accured Expenses over 5 years: stood at -$3.9 million in 2022, then surged by 136.63% to $1.4 million in 2023, then sank by 490.03% to -$5.6 million in 2024, then jumped by 108.75% to $486000.0 in 2025, then tumbled by 840.53% to -$3.6 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.6 million (Q1 2026), $486000.0 (Q4 2025), and -$326000.0 (Q3 2025), per Business Quant data.